小说金色脂质纳米颗粒与小干扰的核糖核酸用于法布里病的基质减少疗法
Marina Beraza-Millor1,2, Julen Rodríguez-Castejón1,2, Jonatan Miranda3,4
1Pharmacokinetic, Nanotechnology and Gene Therapy Group (Pharma Nano Gene), Faculty of Pharmacy, Centro de Investigación Lascaray Ikergunea, University of Basque Country UPV/EHU, 01006 Vitoria-Gasteiz, Spain.
Pharmaceutics
|July 29, 2023
概括
使用siRNA-黄金脂质纳米颗粒 (LNP) 的新纳米药物显示出对法布里病 (FD) 治疗的希望. 这些纳米粒子有效地降低了全球三基胺 (Gb3) 合成酶mRNA,为FD提供了潜在的基因治疗方法.
科学领域:
- 生物医学工程 生物医学工程
- 基因治疗 基因治疗
- 纳米医学是一种纳米医学.
背景情况:
- 费布里病 (FD) 是一种遗传性疾病,其特点是全球酸胺 (Gb3) 的积累.
- 基质减小疗法 (SRT) 是一种潜在的治疗策略,可以防止Gb3的形成.
- 用小干扰RNA (siRNA) 准Gb3合成酶 (Gb3S) 为SRT提供了一种基因沉默方法.
研究的目的:
- 设计和评估用于法布里病的基质还原疗法的新型纳米药物.
- 研究配方因子的影响,包括像金纳米颗粒 (GN) 这样的配体,对siRNA传递和疗效的影响.
- 评估siRNA载脂纳米粒子 (LNP) 在FD细胞模型中的Gb3S基因沉默的潜力.
主要方法:
- 开发含有siRNA的固体脂质纳米颗粒 (SLN),其组成和配体 (GN,原胺,多糖) 不同.
- 在FD细胞模型 (IMFE-1) 中评估纳米粒子内部化,Gb3S mRNA沉默 (RT-qPCR) 和Gb3S蛋白减少 (免疫细胞化学).
- 对开发的纳米药物的系统疗效,稳定性,细胞活力和血红相容性进行评估.
主要成果:
- siRNA金色LNP在FD细胞模型中显示出高效的细胞吸收,GN在细胞质和细胞核中发现.
- 沉默效果因配方而异,达到高达90%的Gb3S mRNA降低.
- 在不影响细胞活力或血红相容性的情况下,GNs增强了系统的有效性和稳定性.
- 在最佳配方中,至少15天的持续Gb3S静音被证实.
结论:
- 开发的siRNA-golden LNP系统是一个有前途的纳米药物,用于法布里病的基质还原疗法.
- 这种方法提供了针对Gb3合成酶的基因沉默,可能防止Gb3积累.
- 进一步的开发可能会导致有效的基于纳米医学的基因治疗法布里病.
相关概念视频
02:30siRNA - Small Interfering RNAs
16.8K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
16.8K
01:23RNA Interference
26.1K
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
26.1K